

EDITORIAL CALENDAR 2025



APRIL

SPECIAL LAUNCH ISSUE

Confirmed contributors include:

Rakesh Dixit Regio Biosciences, Bionavigen, and Tmab Therapeutics
Moein Moghimi Newcastle University and University of Colorado-Denver Medical Center
Helen Bright Centauri Therapeutics
Michelle Morrow Avacta Therapeutics
Yu-Tzu Tai Oxford Biotherapeutics

JUNE

EVOLVING ADCS: EXPANDING HORIZONS

Confirmed contributors include:

Nick Yoder Dyne Therapeutics
Nimish Gupta Regeneron

JULY

TARGETING PRECISION: BIOCONJUGATES IN DIAGNOSTICS AND IMAGING

Confirmed contributors include:

Summer Gibbs Oregon Health and Science University
Kerstin Hofer Roche

SEPTEMBER

NEW FRONTIERS: HOW ARE OLIGONUCLEOTIDE, PEPTIDE, AND OTHER EMERGING CONJUGATES EXTENDING THE REACH OF THE FIELD?

Confirmed contributors include:

Sritama Bose NATA
Vince Rotello University of Massachusetts
Naim Nazef Denali Therapeutics

OCTOBER

DRIVING IMPROVEMENTS IN THE DELIVERY AND STABILITY OF NEXT- GENERATION BIOCONJUGATES, INCLUDING OLIGO, POLYMER, AND ENZYME

Confirmed contributors include:

**Ashutosh Chilkoti, Parul Sirohi,
and Yoyo Ma** Duke University

NOVEMBER

OVERCOMING CHALLENGES IN THE ADC MANUFACTURING AND R&D ECOSYSTEMS

Confirmed contributors include:

Brandon Coyle Gilead Sciences
Eric Lacoste Sanofi
Tiffany Thorn BiVICTriX Therapeutics
Jutta Deckert and Justyna Mysliwi Iksuda Therapeutics
Megan Rice AstraZeneca

Contact **Nicola McCall** on +44 (0)7711 350195 or n.mccall@insights.bio
to discuss thought leadership and lead generation opportunities

EDITORIAL CALENDAR 2025

JOURNAL SPOTLIGHTS

Special launch issue

APR

Evolving ADCs: expanding horizons

JUN

- ▶ Diversifying the therapeutic uses of ADCs—what will follow the example of drugs such as Kadcyla and Adcetris?
 - ▶ Addressing the limitations of ADCs in non-cancer disease areas and identifying viable targets
 - ▶ Minimizing systemic toxicity in ADCs for chronic and autoimmune diseases
- ▶ Enhancing site-specific conjugation to minimize heterogeneity in ADCs
- ▶ Navigating IP challenges to open up opportunities in the ADC landscape
- ▶ Adoption of bi/multifunctional payloads and innovative linker chemistries for precise drug release and stability
 - ▶ Integration of bispecific approaches to target multiple pathways or diseases simultaneously
- ▶ Designing rapidly clearable ADCs and leveraging structure-activity relationships (SAR) to minimize off-target effects
- ▶ Managing geopolitical risk and harnessing dual-sourcing strategies for ADC supply chains

Targeting precision: bioconjugates in diagnostics and imaging

JUL

- ▶ Enhancing sensitivity and specificity in bioconjugates for imaging applications
- ▶ Overcoming challenges in scaling production of PET and SPECT imaging agents
- ▶ Developing more robust conjugation methods for fluorescent and luminescent probes
- ▶ Addressing biocompatibility and immune response risks in diagnostic bioconjugates
- ▶ Solving issues of cross-reactivity and false positives in biomarker detection assays
- ▶ Troubleshooting the integration of bioconjugates into theranostics applications
- ▶ Success factors in scaling up production of radioconjugates and ensuring stability during manufacturing
- ▶ Addressing gaps in the analytical toolkit for the characterization of radioconjugates and imaging agents
- ▶ Enhancing linker chemistries in nanoparticle conjugates to allow for controlled release of imaging agents

New frontiers: how are oligonucleotide, peptide, and other emerging conjugates extending the reach of the field?

SEP

- ▶ Identifying and addressing key gaps in regulatory/CMC guidance for oligonucleotide and peptide conjugates
- ▶ Enabling accurate characterization of non-ADC bioconjugates through standardized analytical tools (HPLC, mass spectrometry)
- ▶ Will advancing these tools improve real-time monitoring of conjugate efficiency and degradation kinetics?
- ▶ Realizing the therapeutic potential of oligonucleotide-based conjugates in targeted medicine
- ▶ Advances in peptide-based drug delivery to overcome endosomal escape barriers
- ▶ How and where is PEGylation being incorporated, and to what effect? (e.g., to decrease immunogenicity)
- ▶ Quantifying the clinical potential of bioconjugates for regenerative medicines and vaccine development
- ▶ Exploring the application of conjugated peptides in vaccines and chronic disease treatments to enhance immune response
- ▶ Solving regulatory hurdles for next-generation vaccine conjugates


EDITORIAL CALENDAR 2025

JOURNAL SPOTLIGHTS

Driving improvements in the delivery and stability of next-generation bioconjugates, including oligo, polymer and enzyme

OCT

- ▶ Enhancing stability and delivery of oligonucleotide conjugates *in vivo*
 - ▶ Maintaining the structural and functional integrity of the bioconjugate components during the manufacturing process
- ▶ Ensuring biocompatibility and controlled release in polymer-drug conjugates
- ▶ Addressing stability challenges in nanoparticle-based conjugates
- ▶ Tackling immunogenicity in polymer- and enzyme-conjugated therapeutics through sustained drug release
- ▶ Developing robust analytical tools for assessing stability and characterizing increasingly complex bioconjugates
- ▶ Improving cell targeting and endosomal escape mechanisms for nanoparticle-drug conjugates



Overcoming challenges in the ADC manufacturing and R&D ecosystems

NOV

- ▶ Addressing *in vivo* challenges related to ADC stability to maintain therapeutic activity until reaching the target
 - ▶ Stabilizing ADCs in physiological environments while ensuring efficient payload release
- ▶ Overcoming endosomal escape inefficiencies for improved cytosolic access
- ▶ Innovating linker design to address stability, biocompatibility, and release kinetics
 - ▶ Assessing the pros and cons of traditional versus emerging ADC manufacturing processes and technologies
- ▶ How to successfully apply click chemistry and enzymatic approaches in bioconjugate manufacturing?
- ▶ Leveraging next-generation analytical tools for enhanced ADC characterization
- ▶ Breaking new ground in antigen targeting and validation
- ▶ Optimizing drug-antibody ratio (DAR) to maximize efficacy while minimizing toxicity
- ▶ Improving dosing regimens—assessing the available tools and strategies (e.g., ADME profiling)

